Table 1:
Clinicopathologic features of patients with endometrial cancer based on the presence or absence of inflammation
| Entire cohort (n=101) |
Cases with RNA-sequencing (n=55) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | Overall n=101 |
CLS + n=46 |
CLS − n=55 |
p- value |
Overall n=55 |
CLS + n=27 |
CLS − n=28 |
p- value |
| Age, years (range) | 60.9 (38.2-92.1) | 65.2 (38.2- | 58.6 (41.5- | 0.017 | 58.6 (38.2- | 65.0 (38.2- | 58.6 (41.5- | 0.048 |
| BMI, kg/m2 | 31.1 (11.4-64.3) | 34.6 (11.4- | 28.5 (12.8- | <0.001 | 32.5 (11.4- | 34.8 (11.4- | 28.5 (12.8- | 0.013 |
| BMI category | 0.006 | 0.025 | ||||||
| Normal <25 kg/m2 | 22 (21.8) | 6 (13.0) | 16 (29.1) | 11 (20.0) | 2 (7.4) | 9 (32.1) | ||
| Overweight 25-29.9 kg/m2 | 24 (23.8) | 7 (15.2) | 17 (30.9) | 9 (16.4) | 4 (14.8) | 5 (17.9) | ||
| Obese ≥30 kg/m2 | 55 (54.5) | 33 (71.7) | 22 (40.0) | 35 (63.6) | 21 (77.8) | 14 (50.0) | ||
| Race | >0.9 | 0.631 | ||||||
| White | 88 (87.1) | 41 (89.1) | 47 (85.5) | 49 (89.1) | 25 (92.6) | 24 (85.7) | ||
| Black | 3 (3.0) | 1 (2.2) | 2 (3.6) | 1 (1.8) | 0 (0) | 1 (3.6) | ||
| Asian | 6 (5.9) | 2 (4.3) | 4 (7.3) | 3 (5.5) | 1 (3.7) | 2 (7.1) | ||
| Declined to answer | 4 (4.0) | 2 (4.3) | 2 (3.6) | 4 (3.6) | 1 (3.7) | 1 (3.6) | ||
| Histology | 0.12 | 0.123 | ||||||
| Endometrioid | 74 (73.3) | 35 (76.1) | 39 (70.9) | 44 (80.0) | 24 (88.9) | 20 (71.4) | ||
| Carcinosarcoma | 2 (2.0) | 0 (0.0) | 2 (3.6) | 2 (3.6) | 0 (0.0) | 2 (7.1) | ||
| Clear cell | 1 (1.0) | 1 (2.2) | 0 (0.0) | 1 (1.8) | 1 (3.7) | 0 (0) | ||
| Serous | 10 (9.9) | 7 (15.2) | 3 (5.5) | 2 (3.6) | 1 (3.7) | 1 (3.6) | ||
| Mixed endometrioid/clear | 5 (5.0) | 2 (4.3) | 3 (5.5) | 2 (3.6) | 1 (3.7) | 1 (3.6) | ||
| Mixed endometrioid/serous | 2 (2.0) | 0 (0.0) | 2 (3.6) | 2 (3.6) | 0 (0.0) | 2 (7.1) | ||
| No residual ca | 7 (6.9) | 1 (2.2) | 6 (10.9) | 2 (3.6) | 0 (0) | 2 (7.1) | ||
| Stage * | 0.9 | 0.217 | ||||||
| Stage I | ||||||||
| IA | 68 (70.8) | 34 (75.6) | 34 (66.7) | 39 (70.9) | 22 (81.5) | 17 (60.7) | ||
| IB | 15 (15.6) | 7 (15.6) | 8 (15.7) | 8 (14.5) | 4 (14.8) | 4 (14.3) | ||
| Stage II | 2 (2.1) | 1 (2.2) | 1 (2.0) | 0 (0) | 0 (0) | 0 (0) | ||
| Stage III | ||||||||
| IIIA | 6 (6.2) | 2 (4.4) | 4 (7.8) | 4 (7.3) | 1 (3.7) | 3 (10.7) | ||
| IIIB | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| IIIC | 4 (4.2) | 1 (2.2) | 3 (5.9) | 2 (3.6) | 0 (0) | 2 (7.1) | ||
| Stage IV | ||||||||
| IVA | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| IVB | 1 (1.0) | 0 (0.0) | 1 (2.0) | 0 (0) | 0 (0) | 0 (0) | ||
| Menopausal status ** | 0.4 | 0.746 | ||||||
| Pre | 23 (23.2) | 8 (18.2) | 15 (27.3) | 12 (21.8) | 5 (18.5) | 7 (25.0) | ||
| Post | 76 (76.8) | 36 (81.8) | 40 (72.7) | 43 (78.2) | 22 (81.5) | 21 (75.0) | ||
| Smoking | 28 (27.7) | 13 (28.3) | 15 (27.3) | >0.9 | 14 (25.5) | 8 (29.6) | 6 (21.4) | 0.547 |
| ETOH *** | 53 (53.0) | 18 (40.0) | 35 (63.6) | 0.031 | 29 (52.7) | 11 (40.7) | 18 (64.3) | 0.079 |
| Hypertension | 51 (50.5) | 32 (69.6) | 19 (34.5) | <0.001 | 27 (49.1) | 20 (74.1) | 7 (25.0) | <0.00 |
| Dyslipidemia | 25 (24.8) | 18 (39.1) | 7 (12.7) | 0.005 | 15 (27.3) | 13 (48.1) | 2 (7.1) | <0.00 |
| Diabetes mellitus | 0.009 | 0.011 | ||||||
| Pre | 6 (5.9) | 6 (13.0) | 0 (0.0) | 5 (9.1) | 5 (18.5) | 0 (0.0) | ||
| Yes | 11 (10.9) | 6 (13.0) | 5 (9.1) | 6 (10.9) | 4 (14.8) | 2 (7.1) | ||
| No | 84 (83.2) | 34 (73.9) | 50 (90.9) | 44 (80.0) | 18 (66.7) | 26 (92.9) | ||
CLS, crown-like structure; BMI, body mass index; ETOH, ethanol/ alcohol. Values are presented as numbers (%) or median (range).
*
1 missing in the CLS-positive group and 4 missing in the CLS-negative group.
**
2 missing in the CLS-positive group.
***
1 missing in the CLS-positive group.